Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis

Rachael M. Duff, Nicholas J. Simmonds, Jane C. Davies, Robert Wilson, Eric W. Alton, Panagiotis Pantelidis, Michael J. Cox, William O.C.M. Cookson, Diana Bilton, Miriam F. Moffatt
European Respiratory Journal 2013 41: 991-993; DOI: 10.1183/09031936.00052712
Rachael M. Duff
*Molecular Genetics and Genomics Section, National Heart and Lung Institute, Imperial College, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas J. Simmonds
#Dept of Cystic Fibrosis, Royal Brompton and Harefield NHS Foundation Trust, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane C. Davies
#Dept of Cystic Fibrosis, Royal Brompton and Harefield NHS Foundation Trust, London
¶Dept of Gene Therapy, National Heart and Lung Institute, Imperial College, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Wilson
+Host Defence Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric W. Alton
#Dept of Cystic Fibrosis, Royal Brompton and Harefield NHS Foundation Trust, London
¶Dept of Gene Therapy, National Heart and Lung Institute, Imperial College, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panagiotis Pantelidis
¶Dept of Gene Therapy, National Heart and Lung Institute, Imperial College, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Cox
*Molecular Genetics and Genomics Section, National Heart and Lung Institute, Imperial College, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William O.C.M. Cookson
*Molecular Genetics and Genomics Section, National Heart and Lung Institute, Imperial College, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Bilton
#Dept of Cystic Fibrosis, Royal Brompton and Harefield NHS Foundation Trust, London
§These two authors contributed equally to the study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam F. Moffatt
*Molecular Genetics and Genomics Section, National Heart and Lung Institute, Imperial College, London
§These two authors contributed equally to the study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.moffatt@imperial.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Chronic bacterial infections play an important role in disease progression in patients with bronchiectasis (BX) and cystic fibrosis (CF). Although only a few per cent of all bacteria can be cultured routinely in the laboratory [1], most bacteria can be identified through sequencing the variable regions of their 16S rRNA gene [2]. DNA studies in patients with CF revealed a more complex microbiota than was identified by standard culture [3, 4], leading us to test by sequencing whether BX may have a similarly complex polymicrobial state.

Approval was gained from the Brompton, Harefield and NHLI Research Ethics Committee and all subjects provided written consent. We collected sputa from 11 patients with BX (mean±sd age years 59.6±11.6) and 10 with CF (mean±sd age years 30.8±5.3). An aliquot of sputum was cultured following CF Trust microbiology guidelines [5]. Following lysis and DNA extraction we amplified a hyper-variable region of the 16S rRNA gene, and cloned, sequenced and analysed the products as described [6]. 96 clones were analysed for each patient. Sequences are stored as GenBank accession numbers JN212577–JN214344.

At the time of study, five of 11 BX patients were being treated with i.v. antibiotics for an acute exacerbation. Four patients were receiving treatment for chronic fungal pulmonary disease. Other antibiotics (oral or nebulised) were being administered long term, either as long-term anti-infective agents (such as nebulised colomycin or tobramycin) or as long-term anti-inflammatory immune modulators (azithromycin). Nine of the 10 CF patients were being treated for an acute exacerbation (eight with i.v. antibiotics and one with oral antibiotics).

A total of 1768 high quality 16S rRNA gene sequences were obtained from the sputum samples of all patients. No amplification of bacterial DNA was obtained for one sample, due to the presence of an unidentified inhibitor of PCR.

A total of 48 different operational taxonomic units (OTUs) (indicating distinct bacterial sequences) was observed in the combined BX and CF samples, consisting of 42 BX group OTUs and 18 CF OTUs. 12 (25%) OTUs were common to both groups (fig. 1). The 48 OTUs were assigned to a genus by a >98% identity match after a BLAST (Basic Local Alignment Search Tool) search of known bacterial 16S rRNA gene sequences using RDP Release 10, update 15 [7].

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Heat map displaying the relative abundance of distinct bacterial species (defined as operational taxonomic units (OTUs)) detected by sequencing the 16S rRNA gene in sputum samples from each patient. The samples are divided into two panels showing results for non-cystic fibrosis bronchiectasis (BX) and cystic fibrosis (CF). The darkness of the bars indicates the relative abundance of each species in sputum samples from each patient. A phylogenetic tree showing the relationship between OTUs is aligned with the heat map to the left and culture results observed for each sputum sample are displayed at the top of the figure.

Pseudomonas aeruginosa was the most common organism detected by sequencing, being present in 81% of BX and 55% of CF patients. When P. aeruginosa was detected in a sample it was invariably the predominant OTU present (fig. 1). Strikingly, P. aeruginosa was detected by sequencing in five patients with negative cultures. We found more than one Pseudomonas spp. OTU present in two patients, supporting the observation that it is common for CF and BX patients to be infected with multiple strains of P. aeruginosa [8]. The 16S rRNA gene cloning results did not discern between P. aeruginosa and its mucoid form.

In the absence of P. aeruginosa other organisms were predominant in the sputum samples, such as: Proteus mirabilis for patient BX4; Achromobacter sp. in patients BX7, BX10, BX15 and CF18; an unclassified Proteobacteria which grouped closely to Haemophilus influenzae and Proteus mirabilis in patient BX16; an unclassified Firmicute which grouped closely to Granulicetalla sp. and Streptococcus sp. in patient BX17; Staphylococcus aureus in patient CF2; Ralstonia sp. in patient CF21; and Stenotrophomonas maltophilia in patients CF22 and CF23. All of these organisms may be pathogens contributing to the disease process.

In only 20% of patients was there a complete agreement between bacteria detected by standard microbial culture and 16S rRNA gene sequencing. There was a partial match between 16S rRNA gene sequence identity and culture results in 35% of samples and no match in 45% of samples. This result is consistent with previous reports that 30% of purulent sputum samples from BX patients fail to culture with standard microbial techniques [9], and confirms that molecular methods can detect the significant presence of bacteria in culture negative patients [10]. Positive cultures were not accompanied by specific sequences in four patients, reflecting the limitations of small numbers of sequenced clones to identify low abundance organisms.

Amongst other common organisms, Streptococcus spp. were detected in 63% of BX patient samples and 30% of CF patient samples. Prevotella spp. were more common in BX (73%) compared to CF (22%). Haemophilus spp. were also present in 45% of BX and 10% of CF patients. In six patients more than one potentially pathogenic bacterium species was detected in >30% of the sample (fig. 1).

We did not estimate bacterial load, but all patients were producing purulent sputum at the time of the study. Inspection of the OTU distribution suggested a greater species diversity in BX patients compared to CF (fig. 1), which was confirmed by Chao estimates of the mean numbers of OTUs per sputum (8.2±5.2 in BX patients and 2.7±2 in patients with CF; p<0.0001, LIBSHUFF estimate=0.004). The microbiome from both sets of specimens was markedly different from that observed in the airways of control samples from adults and children [6]. The small sample and the use of multiple antibiotics made it difficult to dissect out whether the observed levels of diversity were related to acute and chronic antibiotic use, patient age or exacerbation status.

We have studied patients at a single time in the course of a prolonged illness. The technology we have used to obtain sequences (cloning and sequencing) is cumbersome and provides small numbers, and is already being replaced by rapid and potentially high-throughput ultra-deep sequencing of amplicons of the 16S rRNA gene. Our findings are nevertheless consistent with a similar study of resected lungs from patients with these illnesses [11]. Our findings show the limitations of sputum culture in identifying all bacteria that are causal in disease progression. Our results provide hope that the integration of molecular methods into the practice of clinical microbiology will result in an improved level of diagnostic accuracy.

Acknowledgments

We are grateful to Michael Loebinger (Host Defence Unit, Royal Brompton and Harefield NHS Foundation Trust, London and Molecular Genetics and Genomics Section, National Heart and Lung Institute, Imperial College, London, UK) for his thoughtful comments on the paper.

Footnotes

  • Support Statement

    The study was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, by a Research Excellence Award from Imperial College London, and by the Wellcome Trust (Grant number 077959/Z/05/Z).

  • Statement of Interest

    None declared.

  • ©ERS 2013

REFERENCES

  1. ↵
    1. Staley JT,
    2. Konopka A
    . Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats. Annu Rev Microbiol 1985; 39: 321–346.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Turnbaugh PJ,
    2. Ley RE,
    3. Hamady M,
    4. et al
    . The human microbiome project. Nature 2007; 449: 804–810.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Rogers GB,
    2. Carroll MP,
    3. Serisier DJ,
    4. et al
    . Bacterial activity in cystic fibrosis lung infections. Respir Res 2005; 6: 49.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cox MJ,
    2. Allgaier M,
    3. Taylor B,
    4. et al
    . Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010; 5: e11044.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Saiman L,
    2. Siegel J
    . Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24: S6–S52.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Hilty M,
    2. Burke C,
    3. Pedro H,
    4. et al
    . Disordered microbial communities in asthmatic airways. PLoS One 2010; 5: e8578.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cole JR,
    2. Wang Q,
    3. Cardenas E,
    4. et al
    . The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res 2009; 37: D141–D145.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Waine DJ,
    2. Honeybourne D,
    3. Smith EG,
    4. et al
    . Cross-sectional and longitudinal multilocus sequence typing of Pseudomonas aeruginosa in cystic fibrosis sputum samples. J Clin Microbiol 2009; 47: 3444–3448.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. King PT
    . The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 2009; 4: 411–419.
    OpenUrlPubMed
  10. ↵
    1. Rogers GB,
    2. Daniels TW,
    3. Tuck A,
    4. et al
    . Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. BMC Pulm Med 2009; 9: 14.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Maughan H,
    2. Cunningham KS,
    3. Wang PW,
    4. et al
    . Pulmonary bacterial communities in surgically resected noncystic fibrosis bronchiectasis lungs are similar to those in cystic fibrosis. Pulm Med 2012; 2012: 746358.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 41 Issue 4 Table of Contents
European Respiratory Journal: 41 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis
Rachael M. Duff, Nicholas J. Simmonds, Jane C. Davies, Robert Wilson, Eric W. Alton, Panagiotis Pantelidis, Michael J. Cox, William O.C.M. Cookson, Diana Bilton, Miriam F. Moffatt
European Respiratory Journal Apr 2013, 41 (4) 991-993; DOI: 10.1183/09031936.00052712

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis
Rachael M. Duff, Nicholas J. Simmonds, Jane C. Davies, Robert Wilson, Eric W. Alton, Panagiotis Pantelidis, Michael J. Cox, William O.C.M. Cookson, Diana Bilton, Miriam F. Moffatt
European Respiratory Journal Apr 2013, 41 (4) 991-993; DOI: 10.1183/09031936.00052712
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Drug concentration in lung tissue in MDR-TB
  • Obesity in COPD: the effect of water-based exercise
  • Burden of CAP in Italian general practice
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society